Emcure Pharmaceuticals announced on Saturday that it will acquire the remaining 20.42% stake in its subsidiary Zuventus Healthcare Ltd from minority shareholders for a total consideration of ₹724.9 crore.
In a regulatory filing, the company stated that its Board of Directors has approved the proposal to enter into agreements with Zuventus’ minority shareholders to acquire their remaining shareholding. Upon completion of the transaction, Zuventus Healthcare will become a wholly owned subsidiary of Emcure Pharmaceuticals.
The acquisition will be executed through cash payments amounting to ₹724.9 crore, which will be made in one or more tranches at the time of closing, based on the agreed valuation. Currently, Emcure holds a 79.58% stake in Zuventus Healthcare.
The transaction is expected to be finalized during the September quarter of the financial year 2025-26.
Emphasizing the strategic importance of the domestic market, Emcure Pharmaceuticals said that this move will allow full financial consolidation of Zuventus, enhance alignment across its domestic business operations, and unlock significant synergies. The company believes that this acquisition will contribute to long-term value creation for Emcure.